Pharma sales to grow beyond $1 trillion

New findings forecast global pharma sales to grow past 2014’s $1 trillion to $1.3 trillion by 2018

The Intellectual Property and Science business of Thomson Reuters, provider of intelligent information for businesses and professionals announced the release of the 2015 CMR Pharmaceutical R&D Factbook, the biopharmaceutical industry’s leading resource of global R&D trends. Despite concerns around declines in R&D, the analysis identifies a surge in global sales with 2014’s $1 trillion milestone and forecasts sales to reach $1.3 trillion by 2018. It also reveals a positive shift in new molecular entities (NMEs) with 46 launches in 2014; the highest in over a decade.

The study underscores a promising industry outlook with increases in sales and NME launches and with shifting trends in R&D pipeline volume and therapeutic areas as evidenced by other key findings.

Diversification increases NME launches: One third of 2014 launches were for rare indications, mainly within anti-cancer. More than 65 per cent were speciality drugs for the treatment of anti-cancer, Hepatitis C virus and HIV.

Anti-cancer dominates: Anti-cancer development continues to attract the highest amount of investments across all therapeutic areas; with the majority of recent launches receiving orphan drug status from regulatory authorities.

Increase in failing fast and cheaply: Phase III pipeline volumes are steadily growing due to the improved ability to ‘fail fast and cheaply,’ increasing the speed of potentially successful compounds through development.

Since 2003, the CMR Pharmaceutical R&D Factbook has been built in collaboration with leading global pharmaceutical companies to assess productivity and to provide insights to strengthen planning and the effectiveness of R&D. It is based on proprietary, primary sources, competitive intelligence, and public sources covering key trends across the landscape, including R&D pipeline volume, success rates, cycle times, regional comparisons, therapeutic areas, and generics.

“This is an extraordinary year for the pharma,” said Basil Moftah, President, Thomson Reuters IP & Science. “Not only do  the critical insights provided by the Factbook challenge negative perceptions, but it demonstrates this industry’s continued commitment to creating and  employing  innovative solutions to tackle its largest hurdles.”

CMR Pharmaceutical R&D Factbooknew molecular entitiespharmaceutical